Challenges of Duchenne Muscular Dystrophy in the Joseph Family

For Alison Joseph, watching her nine-year-old son Noah enjoy the swimming pool for the first time this summer was a mix of joy and sorrow. While Noah was thrilled to learn how to swim, their mother couldn’t help but think about her older son, Hunter, who at ten years old, is unable to join in.

“Hunter looks at Noah and sees how well he’s doing,” Alison commented. “There’s a sadness because he wishes he could do all those things too.” Both boys have Duchenne muscular dystrophy (DMD), a severe genetic disorder that leads to muscle degeneration and weakness.

This condition, mainly affecting boys, worsens over time, making activities like walking and playing increasingly challenging. Children often miss developmental milestones, and many boys are wheelchair-bound by their teenage years, with life expectancy typically around 30 to 40 years.

In March, Noah received gene therapy through Alison’s health insurance, offering hope for improved mobility. However, when Hunter’s application for the same treatment was submitted in May, it was denied. “They claimed it wasn’t medically necessary,” Allison reported from their home in Winnetka, near Chicago, feeling the weight of the denial deeply.

Alison and her husband, William, who works in finance, are grappling with this difficult situation after receiving a decision from Blue Cross Blue Shield. The experience has been both frustrating and heartbreaking.

I reached out to Blue Cross Blue Shield for clarification on why treatment was approved for Noah but not for Hunter. The company simply replied, “We do not discuss individual cases publicly,” but emphasized that medical professionals guide treatment decisions.

As Hunter’s condition deteriorates, Alison feels helpless watching her son decline. “Every day, his muscles weaken,” she expressed, “and it’s not right that he’s being denied treatment.” The family received the distressing diagnosis of DMD in 2017, after Hunter showed increased liver enzymes. Further tests confirmed the worst.

After Hunter’s diagnosis, both Noah and their 12-year-old brother Carter were also tested. Carter was healthy, but Noah tested positive, adding to Alison’s anguish as she realized she was a carrier of the illness. The family has had to cope with the reality of Hunter’s gradual decline over the years.

But there was a glimmer of hope in 2023 when a new gene therapy by Sarepta Therapeutics received FDA approval. Priced at $3.2 million, this treatment aims to enhance muscle function, though it’s relatively new, leading to some skepticism about its efficacy.

Doctors, however, remain cautiously optimistic. “These gene therapies can change the course of the disease,” said Dr. Aravindan Veerapandiyan of Arkansas Children’s Hospital. Despite its promise, Elevidys has had its share of controversy, with critics arguing the approval was premature and not sufficiently backed by scientific research.

Complicating matters, concerns arose when the FDA investigated the death of an 8-year-old in connection with a different gene therapy, although they later ruled it unrelated. Recommendations to suspend distribution to non-ambulatory patients were made, but Noah and Hunter are both able to walk.

For Alison and William, trying Elevidys felt worth the risk. “We know the progression of the disease and were ready to take that chance,” Alison said. After receiving the treatment, Noah has shown “very obvious improvements,” reporting less fatigue and discomfort that he used to complain about. He even learned to swim this summer.

In stark contrast, Hunter continues to struggle. “People see Noah doing well and don’t understand Hunter’s pain,” Alison remarked, highlighting the emotional toll this situation takes on their family.

After Noah’s treatment was approved, they were hopeful Hunter would receive the same care. But when the insurance denied coverage, it felt like a gut punch. Alison speculated that the insurer quietly changed policies, tightening restrictions on gene therapy coverage for specific genetic mutations after Noah was approved.

The insurance company hasn’t responded to inquiries about this claim. In their quest for justice for Hunter, Alison and William have appealed the insurance decision and contacted local representatives for support, eliciting offers of assistance.

Feeling increasingly desperate, Alison expressed, “We’ve tried to make the best decisions for our kids, but now it feels like our choices have been stripped away.” Time is not on Hunter’s side, and his best chance at a comfortable life hangs in the balance.

With the rapid progression of his condition, Alison lamented, “We’re watching him fade away, and it’s terrifying. This treatment could halt the disease’s impact, and yet here we are.”